Shenzhen Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals Co., Ltd. is a professional pharmaceutical enterprise rooted in China and devoted to improving health worldwide.
Launch date
Employees
Market cap
$5.0b
Enterprise valuation
$4.8b (Public information from Sep 2024)
Share price
CNY31.66 002294.SZ
Shenzhen Guangdong (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.7b | 3.1b | 3.5b | 3.4b | 4.0b | 4.7b | 5.5b |
| % growth | (39 %) | 12 % | 14 % | (3 %) | 20 % | 16 % | 17 % |
| EBITDA | 595m | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | 1.4b |
| % EBITDA margin | 22 % | 35 % | 31 % | 31 % | 26 % | 25 % | 25 % |
| Profit | 60.9m | 534m | 637m | 580m | 648m | 752m | 925m |
| % profit margin | 2 % | 17 % | 18 % | 17 % | 16 % | 16 % | 17 % |
| EV / revenue | 10.5x | 8.8x | 9.7x | 10.2x | 8.0x | 6.7x | 5.8x |
| EV / EBITDA | 48.2x | 25.3x | 30.9x | 32.5x | 30.6x | 26.3x | 23.4x |
| R&D budget | 371m | 357m | 534m | 409m | - | - | - |
| R&D % of revenue | 14 % | 12 % | 15 % | 12 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | CNY1.8b | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Shenzhen Salubris Pharmaceuticals
Edit
exited
ACQUISITION by Shenzhen Salubris Pharmaceuticals Jan 2016
